Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2014, Article ID 381231, 13 pages
http://dx.doi.org/10.1155/2014/381231
Review Article

Effect of Metformin Intervention during Pregnancy on the Gestational Diabetes Mellitus in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

1Southern Medical University, Guangzhou 510000, China
2Ningbo No. 2 Hospital, Ningbo 315010, China
3Navy General Hospital of Chinese PLA, Beijing 100000, China

Received 22 March 2014; Revised 20 April 2014; Accepted 23 April 2014; Published 21 May 2014

Academic Editor: Raffaele Marfella

Copyright © 2014 Zhihong Zhuo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Nestler, D. J. Jakubowicz, W. S. Evans, and R. Pasquali, “Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome,” The New England Journal of Medicine, vol. 338, no. 26 I, pp. 1876–1880, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. E. M. Velazquez, S. G. Mendoza, T. Hamer, F. Sosa, and C. J. Glueck, “Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy,” Metabolism: Clinical and Experimental, vol. 43, no. 5, pp. 647–654, 1994. View at Publisher · View at Google Scholar · View at Scopus
  3. E. Diamanti-Kandarakis, C. Kouli, T. Tsianateli, and A. Bergiele, “Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome,” European Journal of Endocrinology, vol. 138, no. 3, pp. 269–274, 1998. View at Publisher · View at Google Scholar · View at Scopus
  4. C. J. Glueck, P. Wang, R. Fontaine, T. Tracy, and L. Sieve-Smith, “Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome,” Metabolism: Clinical and Experimental, vol. 48, no. 4, pp. 511–519, 1999. View at Google Scholar · View at Scopus
  5. P. Moghetti, R. Castello, C. Negri et al., “Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 1, pp. 139–146, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. L. C. Morin-Papunen, R. M. Koivunen, A. Ruokonen, and H. K. Martikainen, “Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 69, no. 4, pp. 691–696, 1998. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Velázquez M., A. Acosta, and S. G. Mendoza, “Menstrual cyclicity after metformin therapy in polycystic ovary syndrome,” Obstetrics and Gynecology, vol. 90, no. 3, pp. 392–395, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. E. M. Velazquez, S. G. Mendoza, P. Wang, and C. J. Glueck, “Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome,” Metabolism: Clinical and Experimental, vol. 46, no. 4, pp. 454–457, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. V. De Leo, A. La Marca, and F. Petraglia, “Insulin-lowering agents in the management of polycystic ovary syndrome,” Endocrine Reviews, vol. 24, no. 5, pp. 633–667, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Dunaif, K. R. Segal, W. Futterweit, and A. Dobrjansky, “Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome,” Diabetes, vol. 38, no. 9, pp. 1165–1174, 1989. View at Google Scholar · View at Scopus
  11. S. Franks, S. Robinson, and D. S. Willis, “Nutrition, insulin and polycystic ovary syndrome,” Reviews of Reproduction, vol. 1, no. 1, pp. 47–53, 1996. View at Google Scholar · View at Scopus
  12. D. Willis, H. Mason, C. Gilling-Smith, and S. Franks, “Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries,” Journal of Clinical Endocrinology and Metabolism, vol. 81, no. 1, pp. 302–309, 1996. View at Publisher · View at Google Scholar · View at Scopus
  13. A. J. Krentz and C. J. Bailey, “Oral antidiabetic agents: current role in type 2 diabetes mellitus,” Drugs, vol. 65, no. 3, pp. 385–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. S. A. Raptis and G. D. Dimitriadis, “Oral hypoglycemic agents: insulin secretagogues, α-glucosidase inhibitors and insulin sensitizers,” Experimental and Clinical Endocrinology and Diabetes, vol. 109, no. 2, pp. S265–S287, 2001. View at Publisher · View at Google Scholar · View at Scopus
  15. R. S. Hundal, M. Krssak, S. Dufour et al., “Mechanism by which metformin reduces glucose production in type 2 diabetes,” Diabetes, vol. 49, no. 12, pp. 2063–2069, 2000. View at Google Scholar · View at Scopus
  16. C. J. Bailey and R. C. Turner, “Metformin,” The New England Journal of Medicine, vol. 334, no. 9, pp. 574–579, 1996. View at Google Scholar · View at Scopus
  17. M. A. Checa, A. Requena, C. Salvador et al., “Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome,” Human Reproduction Update, vol. 11, no. 4, pp. 375–390, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. E. David, “Poly cystic ovarian syndrome,” The New England Journal of Medicine, vol. 352, pp. 1223–1236, 2005. View at Google Scholar
  19. B. Charles, R. Norris, X. Xiao, and W. Hague, “Population pharmacokinetics of metformin in late pregnancy,” Therapeutic Drug Monitoring, vol. 28, no. 1, pp. 67–72, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. E. Vanky, K. Zahlsen, O. Spigset, and S. M. Carlsen, “Placental passage of metformin in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 83, no. 5, pp. 1575–1578, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. J. E. L. Goh, L. Sadler, and J. Rowan, “Metformin for gestational diabetes in routine clinical practice,” Diabetic Medicine, vol. 28, no. 9, pp. 1082–1087, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. E. Vanky, D. E. Zegher F, M. Díaz et al., “On the potential of metformin to prevent preterm delivery in women with polycystic ovary syndrome-an epi-analysis,” Acta Obstetricia et Gynecologica Scandinavica, vol. 91, no. 12, pp. 1460–1464, 2012. View at Google Scholar
  23. J. P. T. Higgins and S. Green, “Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration,” 2011, http://handbook.cochrane.org/.
  24. Cochrane Menstrual Disorders and Subfertility Group, Resources for review authors. Available at, http://mdsg.cochrane.org/resources-review-authors/.
  25. S. Khattab, I. A. Mohsen, I. Aboul Foutouh et al., “Can metformin reduce the incidence of gestational diabetes mellitus in pregnant women with polycystic ovary syndrome? Prospective cohort study,” Gynecological Endocrinology, vol. 27, no. 10, pp. 789–793, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. E. Vanky, S. Stridsklev, R. Heimstad et al., “Metformin Versus placebo from first trimester to delivery in polycystic ovary syndrome: a randomized, controlled multicenter study,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 12, pp. E448–E455, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. F. H. Nawaz and J. Rizvi, “Continuation of metformin reduces early pregnancy loss in obese pakistani women with polycystic ovarian syndrome,” Gynecologic and Obstetric Investigation, vol. 69, no. 3, pp. 184–189, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. M. R. Begum, N. N. Khanam, E. Quadir et al., “Prevention of gestational diabetes mellitus by continuing metformin therapy throughout pregnancy in women with polycystic ovary syndrome,” Journal of Obstetrics and Gynaecology Research, vol. 35, no. 2, pp. 282–286, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. F. H. Nawaz, R. Khalid, T. Naru, and J. Rizvi, “Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome?” Journal of Obstetrics and Gynaecology Research, vol. 34, no. 5, pp. 832–837, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. K. J. Fougner, E. Vanky, and S. M. Carlsen, “Metformin has no major effects on glucose homeostasis in pregnant women with PCOS: results of a randomized double-blind study,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 68, no. 8, pp. 771–776, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. C. J. Glueck, J. Pranikoff, D. Aregawi, and P. Wang, “Prevention of gestational diabetes by metformin plus diet in patients with polycystic ovary syndrome,” Fertility and Sterility, vol. 89, no. 3, pp. 625–634, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. E. Vanky, K. Å. Salvesen, R. Heimstad, K. J. Fougner, P. Romundstad, and S. M. Carlsen, “Metformin reduces pregnancy complications without affecting androgen levels in pregnant polycystic ovary syndrome women: results of a randomized study,” Human Reproduction, vol. 19, no. 8, pp. 1734–1740, 2004. View at Publisher · View at Google Scholar · View at Scopus
  33. C. J. Glueck, N. Goldenberg, P. Wang, M. Loftspring, and A. Sherman, “Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy,” Human Reproduction, vol. 19, no. 3, pp. 510–521, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. C. J. Glueck, P. Wang, N. Goldenberg, and L. Sieve-Smith, “Pregnancy outcomes among women with polycystic ovary syndrome treated with metformin,” Human Reproduction, vol. 17, no. 11, pp. 2858–2864, 2002. View at Google Scholar · View at Scopus
  35. K. A. Salvesen, E. Vanky, and S. M. Carlsen, “Metformin treatment in pregnant women with polycystic ovary syndrome—is reduced complication rate mediated by changes in the uteroplacental circulation?” Ultrasound in Obstetrics and Gynecology, vol. 29, no. 4, pp. 433–437, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. A. A. Abd El Hameed, H. E. Shreif, and H. E. Mowafy, “The role of continuing metformin therapy during pregnancy in the reduction of gestational diabetes and improving pregnancy outcomes in women with polycystic ovary syndrome,” Middle East Fertility Society Journal, vol. 16, pp. 204–208, 2011. View at Google Scholar
  37. C. M. Boomsma, M. J. C. Eijkemans, E. G. Hughes, G. H. A. Visser, B. C. J. M. Fauser, and N. S. Macklon, “A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome,” Human Reproduction Update, vol. 12, no. 6, pp. 673–683, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Thiebaugeorges and B. Guyard-Boileau, “Obstetrical care in gestational diabetes and management of preterm labour,” Diabetes & Metabolism, vol. 36, no. 6, pp. 672–681, 2010. View at Google Scholar · View at Scopus
  39. C. J. Glueck, P. Wang, S. Kobayashi, H. Phillips, and L. Sieve-Smith, “Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome,” Fertility and Sterility, vol. 77, no. 3, pp. 520–525, 2002. View at Publisher · View at Google Scholar · View at Scopus
  40. C. J. Glueck, S. Bornovali, J. Pranikoff, N. Goldenberg, S. Dharashivkar, and P. Wang, “Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome,” Diabetic Medicine, vol. 21, no. 8, pp. 829–836, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Kocak, E. Caliskan, C. Simsir, and A. Haberal, “Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomiphene citrate-resistant women with polycystic ovary syndrome,” Fertility and Sterility, vol. 77, no. 1, pp. 101–106, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. L. Harborne, R. Fleming, H. Lyall, J. Norman, and N. Sattar, “Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome,” The Lancet, vol. 361, no. 9372, pp. 1894–1901, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Bruni, M. Dei, V. Pontello, and P. Vangelisti, “The management of polycystic ovary syndrome,” Annals of the New York Academy of Sciences, vol. 997, pp. 307–321, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. C. J. Glueck, H. Phillips, D. Cameron, L. Sieve-Smith, and P. Wang, “Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study,” Fertility and Sterility, vol. 75, no. 1, pp. 46–52, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. L. E. Kjerulff, L. Sanchez-Ramos, and D. Duffy, “Pregnancy outcomes in women with polycystic ovary syndrome: a metaanalysis,” American Journal of Obstetrics and Gynecology, vol. 204, no. 6, pp. 558.e1–558.e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. N. Roos, H. Kieler, L. Sahlin, G. Ekman-Ordeberg, H. Falconer, and O. Stephansson, “Risk of adverse pregnancy outcomes in women with polycystic ovary syndrome: population based cohort study,” British Medical Journal, vol. 343, Article ID d6309, 2011. View at Google Scholar · View at Scopus
  47. E. L. Hannan, “Randomized clinical trials and observational studies guidelines for assessing respective strengths and limitations,” JACC: Cardiovascular Interventions, vol. 1, no. 3, pp. 211–217, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. N. Black, “Why we need observational studies to evaluate the effectiveness of health care,” British Medical Journal, vol. 312, no. 7040, pp. 1215–1218, 1996. View at Google Scholar · View at Scopus